Metronomic chemotherapy (MC) represents an emerging strategy in veterinary oncology which involves the continuous or regularly scheduled administration of low-dose chemotherapeutic agents. Unlike conventional protocols known as maximum tolerated dose chemotherapy (MTDC), MC aims to inhibit tumor angiogenesis, stimulate antitumor immune responses, and delay or prevent the emergence of drug resistance. This review is structured into three key sections: the mechanisms of action of MC; its clinical indications in dogs and cats, particularly for advanced or treatment-resistant cancers; and reported outcomes regarding efficacy, safety, and tolerability. Additionally, we explore the growing interest in combining MC with other therapies, as well as the challenges and future directions for optimizing its use. Current evidence suggests that MC is a promising and well-tolerated option for managing various malignancies—such as carcinomas, sarcomas, and hemangiosarcomas—especially in patients who are not candidates for MTDC.
节拍化疗（Metronomic chemotherapy，MC）是兽医肿瘤学领域一种新兴的治疗策略，其核心在于持续或规律性地给予低剂量化疗药物。与传统的大剂量耐受化疗（MTDC）方案不同，MC旨在抑制肿瘤血管生成、刺激抗肿瘤免疫反应，并延缓或防止耐药性的出现。本综述分为三个关键部分：MC的作用机制；其在犬猫中的临床应用指征，特别是针对晚期或难治性癌症；以及关于其疗效、安全性和耐受性的现有报告结果。此外，本文还探讨了MC与其他疗法联合应用日益增长的研究兴趣，以及优化其临床应用所面临的挑战和未来方向。现有证据表明，MC对于管理多种恶性肿瘤（如癌、肉瘤和血管肉瘤）是一种前景广阔且耐受性良好的选择，尤其适用于不适合接受MTDC治疗的患者。
Metronomic Chemotherapy in Dogs and Cats: Mechanisms, Indications, and Clinical Perspectives
肿瘤(癌症)患者之家